Neuroendocrine tumors comprise a broad family of tumors, the most common of which are carcinoid and pancreatic neuroendocrine tumors. The NCCN Neuroendocrine Tumors Guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine tumors. Most of the recommendations pertain to well-differentiated, low- to intermediate-grade tumors. This updated version of the NCCN Guidelines includes a new section on pathology for diagnosis and reporting and revised recommendations for the surgical management of neuroendocrine tumors of the pancreas.

  • 1

    YaoJCHassanMPhanA. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol2008;26:30633072.

    • Search Google Scholar
    • Export Citation
  • 2

    MarxSSpiegelAMSkarulisMC. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med1998;129:484494.

  • 3

    Donis-KellerHDouSChiD. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet1993;2:851856.

  • 4

    AnlaufMGarbrechtNBauersfeldJ. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch2007;451Suppl 1:S2938.

    • Search Google Scholar
    • Export Citation
  • 5

    LarsonAMHedgireSSDeshpandeV. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genetin press.

  • 6

    JensonRTNortonJA. Carcinoid tumors and carcinoid syndrome. In: DeVitaVTHellmanSRosenbergSA eds. Cancer: Principles and Practice of Oncology. Vol 2ed 6. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:18131826.

    • Search Google Scholar
    • Export Citation
  • 7

    JoyntKEMoslehiJJBaughmanKL. Paragangliomas: etiology, presentation, and management. Cardiol Rev2009;17:159164.

  • 8

    KlimstraDSArnoldRCapellaC. Neuroendocrine neoplasms of the pancreas. In: BosmanFTCarneiroFHrubanRHTheiseND eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC; 2010:322326.

    • Search Google Scholar
    • Export Citation
  • 9

    PanzutoFBoninsegnaLFazioN. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol2011;29:23722377.

    • Search Google Scholar
    • Export Citation
  • 10

    PanzutoFNasoniSFalconiM. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer2005;12:10831092.

    • Search Google Scholar
    • Export Citation
  • 11

    RindiGKloppelGAlhmanH. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch2006;449:395401.

    • Search Google Scholar
    • Export Citation
  • 12

    HochwaldSNZeeSConlonKC. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol2002;20:26332642.

    • Search Google Scholar
    • Export Citation
  • 13

    PapeUFJannHMuller-NordhornJ. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer2008;113:256265.

    • Search Google Scholar
    • Export Citation
  • 14

    EdgeSBByrdDRComptonCC. eds. AJCC Cancer Staging Manual7th ed.New York, NY: Springer; 2010.

  • 15

    LandryCSWoodallCScogginsCR. Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. Arch Surg2008;143:664670; discussion 670.

    • Search Google Scholar
    • Export Citation
  • 16

    LandryCSBrockGScogginsCR. A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients. Surgery2008;144:460466.

    • Search Google Scholar
    • Export Citation
  • 17

    LandryCSBrockGScogginsCR. A proposed staging system for small bowel carcinoid tumors based on an analysis of 6,380 patients. Am J Surg2008;196:896903; discussion 903.

    • Search Google Scholar
    • Export Citation
  • 18

    LandryCSBrockGScogginsCR. Proposed staging system for colon carcinoid tumors based on an analysis of 2,459 patients. J Am Coll Surg2008;207:874881.

    • Search Google Scholar
    • Export Citation
  • 19

    LandryCSBrockGScogginsCR. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol2009;16:5160.

    • Search Google Scholar
    • Export Citation
  • 20

    StrosbergJRCheemaAWeberJ. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol2011;29:30443049.

    • Search Google Scholar
    • Export Citation
  • 21

    BilimoriaKYBentremDJMerkowRP. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg2007;205:558563.

    • Search Google Scholar
    • Export Citation
  • 22

    HalfdanarsonTRRabeKGRubinJPetersenGM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol2008;19:17271733.

    • Search Google Scholar
    • Export Citation
  • 23

    BallianNLoefflerAGRajamanickamV. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford)2009;11:422428.

    • Search Google Scholar
    • Export Citation
  • 24

    KlimstraDSModlinIRAdsayNV. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol2010;34:300313.

    • Search Google Scholar
    • Export Citation
  • 25

    AlexandrakiKIGrossmanAB. The ectopic ACTH syndrome. Rev Endocr Metab Disord2010;11:117126.

  • 26

    PasiekaJLMcKinnonJGKinnearS. Carcinoid syndrome symposium on treatment modalities for gastrointestinal carcinoid tumours: symposium summary. Can J Surg2001;44:2532.

    • Search Google Scholar
    • Export Citation
  • 27

    SogaJYakuwaYOsakaM. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res1999;18:133141.

  • 28

    ThorsonAH. Studies on carcinoid disease. Acta Med Scand Suppl1958;334:1132.

  • 29

    GilliganCJLawtonGPTangLH. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol1995;90:338352.

    • Search Google Scholar
    • Export Citation
  • 30

    ObergKKvolsLCaplinM. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol2004;15:966973.

    • Search Google Scholar
    • Export Citation
  • 31

    MoertelCGWeilandLHNagorneyDMDockertyMB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med1987;317:16991701.

  • 32

    SandorAModlinIM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol1998;93:422428.

  • 33

    MullenJTSavareseDM. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol2011;104:4144.

  • 34

    SogaJ. Carcinoids of the rectum: an evaluation of 1271 reported cases. Surg Today1997;27:112119.

  • 35

    YaoJCLombard-BohasCBaudinE. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol2010;28:6976.

    • Search Google Scholar
    • Export Citation
  • 36

    CwiklaJBBuscombeJRCaplinME. Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. Med Sci Monit2004;10(Suppl 3):916.

    • Search Google Scholar
    • Export Citation
  • 37

    KaltsasGRockallAPapadogiasD. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol2004;151:1527.

    • Search Google Scholar
    • Export Citation
  • 38

    GlazerESTsengJFAl-RefaieW. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford)2011;12:427433.

    • Search Google Scholar
    • Export Citation
  • 39

    BrentjensRSaltzL. Islet cell tumors of the pancreas: the medical oncologist’s perspective. Surg Clin North Am2001;81:527542.

  • 40

    JansonETObergK. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol1993;32:225229.

    • Search Google Scholar
    • Export Citation
  • 41

    KvolsLKMoertelCGO’ConnellMJ. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med1986;315:663666.

    • Search Google Scholar
    • Export Citation
  • 42

    AndersonASKraussDLangR. Cardiovascular complications of malignant carcinoid disease. Am Heart J1997;134:693702.

  • 43

    JacobsenMBNitter-HaugeSBrydePEHanssenLE. Cardiac manifestations in mid-gut carcinoid disease. Eur Heart J1995;16:263268.

  • 44

    BhattacharyyaSToumpanakisCChilkundaD. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol2011;107:12211226.

    • Search Google Scholar
    • Export Citation
  • 45

    RinkeAMullerHHSchade-BrittingerC. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol2009;27:46564663.

    • Search Google Scholar
    • Export Citation
  • 46

    LiuDMKennedyATurnerD. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol2009;32:200215.

    • Search Google Scholar
    • Export Citation
  • 47

    SipersteinAERogersSJHansenPDGitomirskyA. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery1997;122:11471154; discussion 1154.

    • Search Google Scholar
    • Export Citation
  • 48

    StrosbergJRWeberJMChoiJ. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncolin press.

    • Search Google Scholar
    • Export Citation
  • 49

    GatesJHartnellGGStuartKEClouseME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics1999;19:399414.

    • Search Google Scholar
    • Export Citation
  • 50

    RuszniewskiPMalkaD. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion2000;62(Suppl 1):7983.

    • Search Google Scholar
    • Export Citation
  • 51

    KalinowskiMDresslerMKonigA. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion2009;79:137142.

    • Search Google Scholar
    • Export Citation
  • 52

    KennedyASDezarnWAMcNeillieP. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol2008;31:271279.

    • Search Google Scholar
    • Export Citation
  • 53

    KingJQuinnRGlennDM. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer2008;113:921929.

    • Search Google Scholar
    • Export Citation
  • 54

    MemonKLewandowskiRJMulcahyMF. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Physin press.

    • Search Google Scholar
    • Export Citation
  • 55

    MurthyRKamatPNunezR. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol2008;19:145151.

    • Search Google Scholar
    • Export Citation
  • 56

    RheeTKLewandowskiRJLiuDM. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg2008;247:10291035.

    • Search Google Scholar
    • Export Citation
  • 57

    FazioNde BraudFDelle FaveGObergK. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?Ann Oncol2007;18:1319.

    • Search Google Scholar
    • Export Citation
  • 58

    FjallskogMLSundinAWestlinJE. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol2002;19:3542.

    • Search Google Scholar
    • Export Citation
  • 59

    KolbyLPerssonGFranzenSAhrenB. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg2003;90:687693.

    • Search Google Scholar
    • Export Citation
  • 60

    FaissSPapeUFBohmigM. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol2003;21:26892696.

    • Search Google Scholar
    • Export Citation
  • 61

    YaoJCShahMHItoT. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med2011;364:514523.

  • 62

    YaoJCPhanATChangDZ. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol2008;26:43114318.

    • Search Google Scholar
    • Export Citation
  • 63

    PavelMEHainsworthJDBaudinE. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet2011;378:20052012.

    • Search Google Scholar
    • Export Citation
  • 64

    ParithivelKRamaiyaNJagannathanJP. Everolimus- and temsirolimus-associated enteritis: report of three cases. J Clin Oncol2010;29:e404406.

    • Search Google Scholar
    • Export Citation
  • 65

    ImhofABrunnerPMarincekN. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol2011;29:24162423.

    • Search Google Scholar
    • Export Citation
  • 66

    KrenningEPTeunissenJJMValkemaR. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. J Endocrinol Invest2005;28:146150.

    • Search Google Scholar
    • Export Citation
  • 67

    KwekkeboomDJBakkerWHKamBL. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3] octreotate. Eur J Nucl Med Mol Imaging2003;30:417422.

    • Search Google Scholar
    • Export Citation
  • 68

    KwekkeboomDJTeunissenJJBakkerWH. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol2005;23:27542762.

    • Search Google Scholar
    • Export Citation
  • 69

    KwekkeboomDJTeunissenJJKamBL. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am2007;21:561573.

    • Search Google Scholar
    • Export Citation
  • 70

    GulenchynKYYaoXAsaSL. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol)2012;24:294308.

    • Search Google Scholar
    • Export Citation
  • 71

    Bonaccorsi-RianiEApesteguiCJouret-MourinA. Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transpl Int2010;23:668678.

    • Search Google Scholar
    • Export Citation
  • 72

    GedalyRDailyMFDavenportD. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg2011;146:953958.

    • Search Google Scholar
    • Export Citation
  • 73

    LehnertT. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation1998;66:13071312.

    • Search Google Scholar
    • Export Citation
  • 74

    Le TreutYGGregoireEBelghitiJ. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant2008;8:12051213.

    • Search Google Scholar
    • Export Citation
  • 75

    RosenauJBahrMJvon WasielewskiR. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation2002;73:386394.

    • Search Google Scholar
    • Export Citation
  • 76

    YaoJCEisnerMPLearyC. Population-based study of islet cell carcinoma. Ann Surg Oncol2007;14:34923500.

  • 77

    MooreFDScoinskiMAJosteNE. Endocrine tumors and malignancies. In: SkarinA ed. Atlas of Diagnostic Oncology3rd ed.Philadelphia, PA: Elsevier Science Limited; 2003.

    • Search Google Scholar
    • Export Citation
  • 78

    AlexakisNNeoptolemosJP. Pancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol2008;22:183205.

  • 79

    KulkeMHBendellJKvolsL. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol2011;4:29.

  • 80

    BerniniGPMorettiAFerdeghiniM. A new human chromogranin ‘A’ immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer2001;84:636642.

    • Search Google Scholar
    • Export Citation
  • 81

    CampanaDNoriFPiscitelliL. Chromogranin A: is it a useful marker of neuroendocrine tumors?J Clin Oncol2007;25:19671973.

  • 82

    NeharDLombard-BohasCOlivieriS. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf)2004;60:644652.

    • Search Google Scholar
    • Export Citation
  • 83

    JensenRTFrakerDL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA1994;271:14291435.

    • Search Google Scholar
    • Export Citation
  • 84

    RoschTLightdaleCJBotetJF. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med1992;326:17211726.

  • 85

    DoppmanJLChangRFrakerDL. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med1995;123:269273.

    • Search Google Scholar
    • Export Citation
  • 86

    FajansSSVinikAI. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am1989;18:4574.

  • 87

    ComiRGordonPDoppmanJ. Insulinoma. In: GoVLDi-MagnoEPGardnerJD. eds. The Pancreas: Biology Pathology and Disease2nd ed.New York, NY: Raven Press; 1993.

    • Search Google Scholar
    • Export Citation
  • 88

    CreutzfeldtW. Insulinomas: clinical presentation, diagnosis, and advances in management. In: JensenRTMignonM eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Basel, Switzerland: Karger; 1994:148165.

    • Search Google Scholar
    • Export Citation
  • 89

    StehouwerCDLemsWFFischerHR. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh)1989;121:3440.

    • Search Google Scholar
    • Export Citation
  • 90

    HaynesABDeshpandeVIngkakulT. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg2011;146:534538.

    • Search Google Scholar
    • Export Citation
  • 91

    FerroneCRTangLHTomlinsonJ. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?J Clin Oncol2007;25:56095615.

    • Search Google Scholar
    • Export Citation
  • 92

    ParekhJRWangSCBergslandEK. Lymph node sampling rates and predictors of nodal metastases in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreasin press.

    • Search Google Scholar
    • Export Citation
  • 93

    StrosbergJRCheemaAKvolsLK. Stage I nonfunctioning neuroendocrine tumors of the pancreas: surgery or surveillance? [abstract]. J Clin Oncol2011;29(Suppl 4):Abstract 349.

    • Search Google Scholar
    • Export Citation
  • 94

    BoninsegnaLPanzutoFPartelliS. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancerin press.

    • Search Google Scholar
    • Export Citation
  • 95

    CasadeiRRicciCPezzilliR. Are there prognostic factors related to recurrence in pancreatic endocrine tumors?Pancreatology2010;10:3338.

    • Search Google Scholar
    • Export Citation
  • 96

    KimSJKimJWOhDY. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung). Am J Clin Oncolin press.

    • Search Google Scholar
    • Export Citation
  • 97

    De JongMCFarnellMBSclabasG. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg2010;252:142148.

    • Search Google Scholar
    • Export Citation
  • 98

    MayoSCde JongMCPulitanoC. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol2010;17:31293136.

    • Search Google Scholar
    • Export Citation
  • 99

    PommierRFWolinEMPanneerselvamA. Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): results from the RADIANT-3 trial [abstract]. J Clin Oncol2011;29(Suppl):Abstract 4103.

    • Search Google Scholar
    • Export Citation
  • 100

    ShahMHLombard-BohasCItoT. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial [abstract]. J Clin Oncol2011;29(Suppl):Abstract 4010.

    • Search Google Scholar
    • Export Citation
  • 101

    RaymondEDahanLRaoulJL. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med2011;364:501513.

  • 102

    RaymondENiccoliPRaoulJ. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET) [abstract]. J Clin Oncol2011;29(Suppl):Abstract 4008.

    • Search Google Scholar
    • Export Citation
  • 103

    RichardsCJJeYSchutzFA. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol2011;29:34503456.

    • Search Google Scholar
    • Export Citation
  • 104

    MoertelCGLefkopouloMLipsitzS. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med1992;326:519523.

    • Search Google Scholar
    • Export Citation
  • 105

    KouvarakiMAAjaniJAHoffP. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol2004;22:47624771.

    • Search Google Scholar
    • Export Citation
  • 106

    EkebladSSundinAJansonET. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res2007;13:29862991.

    • Search Google Scholar
    • Export Citation
  • 107

    KulkeMHStuartKEnzingerPC. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol2006;24:401406.

    • Search Google Scholar
    • Export Citation
  • 108

    KulkeMHStuartKEarleCC. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors [abstract]. J Clin Oncol2006;24(Suppl):Abstract 4044.

    • Search Google Scholar
    • Export Citation
  • 109

    KulkeMHHornickJLFrauenhofferC. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res2009;15:338345.

    • Search Google Scholar
    • Export Citation
  • 110

    StrosbergJRFineRLChoiJ. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer2011;117:268275.

    • Search Google Scholar
    • Export Citation
  • 111

    BloomstonMMuscarellaPShahMH. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg2006;10:13611370.

    • Search Google Scholar
    • Export Citation
  • 112

    GomezDMalikHZAl-MuktharA. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford)2007;9:345351.

    • Search Google Scholar
    • Export Citation
  • 113

    PederzoliPFalconiMBonoraA. Cytoreductive surgery in advanced endocrine tumours of the pancreas. Ital J Gastroenterol Hepatol1999;31(Suppl):S207212.

    • Search Google Scholar
    • Export Citation
  • 114

    GurusamyKSPamechaVSharmaDDavidsonBR. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-enteropancreatic neuroendocrine tumours. Cochrane Database Syst Rev2009;21:CD007118.

    • Search Google Scholar
    • Export Citation
  • 115

    StrosbergJRCheemaACamposT. Phase II study of sunitinib malate following hepatic artery embolization for metastatic neuroendocrine tumors [abstract]. J Clin Oncol2011;29(Suppl 4):Abstract 244.

    • Search Google Scholar
    • Export Citation
  • 116

    PerryLJStuartKStokesKRClouseME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery1994;116:11111116.

  • 117

    MatheZTagkalosEPaulA. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation2011;91:575582.

    • Search Google Scholar
    • Export Citation
  • 118

    AllolioBFassnachtM. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab2006;91:20272037.

  • 119

    DackiwAPLeeJEGagelRFEvansDB. Adrenal cortical carcinoma. World J Surg2001;25:914926.

  • 120

    SolciaERindiGPaolottiD. Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Ann Oncol1999;10(Suppl 2):S915.

    • Search Google Scholar
    • Export Citation
  • 121

    CrucittiFBellantoneRFerranteA. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery1996;119:161170.

    • Search Google Scholar
    • Export Citation
  • 122

    WootenMDKingDK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer1993;72:31453155.

    • Search Google Scholar
    • Export Citation
  • 123

    KochCAPacakKChrousosGP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab2002;87:53675384.

    • Search Google Scholar
    • Export Citation
  • 124

    LynchHTRadfordBLynchJF. SBLA syndrome revisited. Oncology1990;47:7579.

  • 125

    SoonPSHMcDonaldKLRobinsonBGSidhuSB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist2008;13:548561.

  • 126

    BrandiMLGagelRFAngeliA. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab2001;86:56585671.

  • 127

    OhgakiHKleihuesPHeitzPU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer1993;54:408410.

  • 128

    ReinckeMKarlMTravisWH. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab1994;78:790794.

    • Search Google Scholar
    • Export Citation
  • 129

    GicquelCBertagnaXSchneidH. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab1994;78:14441453.

    • Search Google Scholar
    • Export Citation
  • 130

    GicquelCRaffin-SansonMLGastonV. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab1997;82:25592565.

    • Search Google Scholar
    • Export Citation
  • 131

    NgLLibertinoJM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol2003;169:511.

  • 132

    BertagnaCOrthDN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med1981;71:855875.

    • Search Google Scholar
    • Export Citation
  • 133

    LutonJPCerdasSBillaudL. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med1990;322:11951201.

    • Search Google Scholar
    • Export Citation
  • 134

    Kasperlik-ZaluskaAAMigdalskaBMZgliczynskiSMakowskaAM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer1995;75:25872591.

    • Search Google Scholar
    • Export Citation
  • 135

    GrahamPESmytheGAEdwardsGALazarusL. Laboratory diagnosis of phaeochromocytoma: which analytes should we measure?Ann Clin Biochem1993;30(Pt 2):129134.

    • Search Google Scholar
    • Export Citation
  • 136

    PeplinskiGRNortonJA. The predictive value of diagnostic tests for pheochromocytoma. Surgery1994;116:11011109.

  • 137

    NearyNMKingKSPacakK. Drugs and pheochromocytoma— don’t be fooled by every elevated metanephrine. N Engl J Med2011;364:22682270.

  • 138

    NortonJALeHN. Adrenal tumors cancer. In: DeVitaVTHellmanSRosenbergSA eds. Cancer: Principles and Practice of Oncology. Vol. 26th ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2001:17701780.

    • Search Google Scholar
    • Export Citation
  • 139

    FunderJWCareyRMFardellaC. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab2008;93:32663281.

    • Search Google Scholar
    • Export Citation
  • 140

    SaundersBDDohertyGM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol2004;5:718726.

  • 141

    ShenWTSturgeonCDuhQY. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol2005;89:186192.

    • Search Google Scholar
    • Export Citation
  • 142

    GuignatLBertheratJ. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. Eur J Endocrinol2010;163:913.

    • Search Google Scholar
    • Export Citation
  • 143

    CaoiliEMKorobkinMFrancisIR. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology2002;222:629633.

    • Search Google Scholar
    • Export Citation
  • 144

    BolandGWLeeMJGazelleGS. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol1998;171:201204.

    • Search Google Scholar
    • Export Citation
  • 145

    ChangAGlazerHSLeeJK. Adrenal gland: MR imaging. Radiology1987;163:123128.

  • 146

    SchultzCLHaagaJRFletcherBD. Magnetic resonance imaging of the adrenal glands: a comparison with computed tomography. AJR Am J Roentgenol1984;143:12351240.

    • Search Google Scholar
    • Export Citation
  • 147

    DicksteinGShechnerCAradE. Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma?J Clin Endocrinol Metab1998;83:31003103.

    • Search Google Scholar
    • Export Citation
  • 148

    Khorram-ManeshAAhlmanHJanssonS. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg1998;22:605611.

    • Search Google Scholar
    • Export Citation
  • 149

    Vassilopoulou-SellinRGuineeVFKleinMJ. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer1993;71:31193123.

    • Search Google Scholar
    • Export Citation
  • 150

    TerzoloMAngeliAFassnachtM. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med2007;356:23722380.

  • 151

    BarzonLFalloFSoninoN. Adrenocortical carcinoma: experience in 45 patients. Oncology1997;54:490496.

  • 152

    BaudinEPellegritiGBonnayM. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer2001;92:13851392.

    • Search Google Scholar
    • Export Citation
  • 153

    HaakHRHermansJvan de VeldeCJ. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer1994;69:947951.

    • Search Google Scholar
    • Export Citation
  • 154

    VeytsmanINiemanLFojoT. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol2009;27:46194629.

    • Search Google Scholar
    • Export Citation
  • 155

    BerrutiATerzoloMSperoneP. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer2005;12:657666.

    • Search Google Scholar
    • Export Citation
  • 156

    KhanTSImamHJuhlinC. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol2000;11:12811287.

    • Search Google Scholar
    • Export Citation
  • 157

    First international randomized trial in locally advanced and metastatic adrenocortical carcinoma treatment (FIRM-ACT) etoposide doxorubicin cisplatin and mitotane vs streptozotocin and mitotane. Bethesda, MD: National Cancer Institute (NCI); 2011.

    • Search Google Scholar
    • Export Citation
  • 158

    KulkeMHSiuLLTepperJE. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol2011;29:934943.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 603 603 65
PDF Downloads 134 134 6
EPUB Downloads 0 0 0